Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




MRI Homepage

AI comparable to radiologists in prostate cancer detection accuracy Identifies and predicts aggressiveness using MR scans

New study shows value of 7T MR for evaluating MS progression Can detect cortical lesions better than conventional scanners

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

The benefits of intraoperative MR Q&A with Dr. John Huston Mayo Clinic neuroradiologist discusses what the advanced capabilities mean for patients – as well as providers

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

Gadolinium not required in 3T MR multiple sclerosis follow-up scans Longitude subtraction mapping just as sensitive: study

New MR methodology may distinguish benign and cancerous lymph nodes Could be used before surgery and help determine treatment

FDA gives thumbs-up to Genetesis MCG cardiac imaging system Measures magnetic fields produced by heart's electrical activity

BSWH to install Glassbeam's CLEAN blueprint to leverage machine uptime Will include integrated CMMS software by EQ2

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

A new contrast agent can differentiate
between aggressive and slow-growing,
low-risk types of breast cancer at
early stages

New MR contrast agent distinguishes aggressive from slow-growing breast cancer

by John R. Fischer , Staff Reporter
Researchers at Case Western Reserve University in Cleveland have created a new MR contrast agent that can locate and differentiate between aggressive and slow-growing, low-risk types of breast cancer at early stages.

The gadolinium-based agent lights up cancer biomarkers during scans, overcoming the low sensitivity of MR for imaging markers, and produces signals with different shades of brightness that contrast aggressive from slow-growing, low-risk types of cancer. The findings were published in the journal, Nature Communications.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

“Current contrast agents do not have the ability to differentiate aggressive breast cancers from low-risk ones,” Dr. Zheng-Rong Lu, the M. Frank Rudy and Margaret Domiter Rudy professor of biomedical engineering at Case Western Reserve and leader of the research, told HCB News. “Current clinical imaging technology doesn't have this ability either.

ZD2 peptide-targeted gadofullerene, the chemical name for the agent, is derived from tri-gadolinium nitride metallofullerene (Gd3N@C80) and ZD2, a peptide developed in Lu’s lab.

Unlike gadolinium in traditional agents, ZD2 peptide-targeted gadofullerene consists of gadolinium ions encased in a hollow molecule of fullerene that takes on the shape of a soccer ball and prevents the ions from interacting with human tissue. ZD2 is applied to the surface of the molecule and specifically targets the cancer protein, extradomain-B fibronectin (EDB-FN).

An MR test conducted on six mouse models found that the accumulation of contrast molecules on three aggressive triple-negative breast cancers (MDA-MB-231, Hs578T and BT549) produced a brighter signal compared to slow-moving, estrogen receptor-positive (ER-positive) breast cancers (MCF-7, ZR-75-1 and T47D), the signal of which was muted due to a lesser accumulation of molecules.

In addition to breast cancer, ZD2 peptide-targeted gadofullerene can also be used to differentiate between aggressive and benign forms of prostate cancer, according to preliminary tests, and possibly other types of cancer, based on the biology of the biomarker. It is currently being tested for the same effect in pancreatic cancer.

The agent is also safer and more effective than traditional agents, requiring a gadolinium dose 20-times smaller, and can easily be flushed from the body without accruing in tissues, as found by the researchers during testing.

Lu says that the ZD2 peptide-targeted gadofullerene could possibly become a standard tool among physicians.

”It has the potential to address the drawbacks and limitations of the existing agents,” he said.

Lu and his colleagues are currently working to determine ways to reduce costs for producing the agent, to make it more attractive for clinical use.

ZD2 peptide-targeted gadofullerene does not yet have a commercial name and has not been submitted for FDA approval. However, a similar agent with the same effect is in clinical development for FDA approval.

MRI Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.